Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

Share this content:
Median metastasis-free survival among patients in the apalutamide arm was 40.5 months, compared with 16.2 months in the placebo arm.
Median metastasis-free survival among patients in the apalutamide arm was 40.5 months, compared with 16.2 months in the placebo arm.

Apalutamide significantly prolongs metastasis-free survival and time to symptomatic progression compared with placebo among men with nonmetastatic castration-resistant prostate cancer (CRPC) not susceptible to androgen-deprivation therapy (ADT), according to a study published in The New England Journal of Medicine.

ADT is an effective early therapy for non-metastatic CRPC, but most patients eventually develop castration-resistant disease. A previous study demonstrated that apalutamide prevented elevations of prostate-specific antigen (PSA), a prognostic factor for the development of metastases. 


For the SPARTAN phase 3 study, researchers randomly assigned 1207 men characterized as high-risk for developing metastases who had a PSA doubling time for 10 months or less to receive apalutamide 250 mg daily or placebo; all patients continued ADT throughout the study. Eligible patients had castration-resistant disease and were confirmed as not having metastatic disease, local, or regional nodal disease at baseline.


The planned primary analysis ― which was conducted after 378 events occurred — showed that the median metastasis-free survival among patients in the apalutamide arm was 40.5 months compared with 16.2 months in the placebo arm (P < .001).

Patients treated with apalutamide also had a significantly prolonged median time to symptomatic progression, progression-free survival, and time to metastasis, compared with placebo (P < .001).

Adverse events that were observed more frequently in the apalutamide arm included rash, hypothyroidism, and fracture.

The authors concluded that “among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival was significantly longer with apalutamide than with placebo. Consistent improvements in secondary and exploratory end points provide support for the veracity of our primary finding.”

Reference

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018 Feb 8. doi: 10.1056/NEJMoa1715546 [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs